JP2008515439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515439A5 JP2008515439A5 JP2007535869A JP2007535869A JP2008515439A5 JP 2008515439 A5 JP2008515439 A5 JP 2008515439A5 JP 2007535869 A JP2007535869 A JP 2007535869A JP 2007535869 A JP2007535869 A JP 2007535869A JP 2008515439 A5 JP2008515439 A5 JP 2008515439A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- polynucleotide
- amino acid
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 47
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 14
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 108010029697 CD40 Ligand Proteins 0.000 claims description 11
- 102100032937 CD40 ligand Human genes 0.000 claims description 11
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 230000011664 signaling Effects 0.000 claims description 9
- 102100035793 CD83 antigen Human genes 0.000 claims description 7
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 7
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 7
- 238000004520 electroporation Methods 0.000 claims description 6
- 102100037850 Interferon gamma Human genes 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 4
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 210000004443 dendritic cell Anatomy 0.000 claims 29
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 108091033319 polynucleotide Proteins 0.000 claims 22
- 102000040430 polynucleotide Human genes 0.000 claims 22
- 239000002157 polynucleotide Substances 0.000 claims 22
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 20
- 125000000539 amino acid group Chemical group 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 239000000556 agonist Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229940123189 CD40 agonist Drugs 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 108010085650 interferon gamma receptor Proteins 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 244000052769 pathogen Species 0.000 claims 4
- 230000001717 pathogenic effect Effects 0.000 claims 4
- 101150013553 CD40 gene Proteins 0.000 claims 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000012642 immune effector Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 108091027963 non-coding RNA Proteins 0.000 claims 2
- 102000042567 non-coding RNA Human genes 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- MYYARUCLXARAEE-ZATZPJRKSA-N alpha-C-GalCer Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCCCCC MYYARUCLXARAEE-ZATZPJRKSA-N 0.000 claims 1
- 125000003550 alpha-D-galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims 1
- 239000013592 cell lysate Substances 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 229960002986 dinoprostone Drugs 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- -1 β-arabinosylceramide Chemical compound 0.000 claims 1
- 230000035800 maturation Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52251204P | 2004-10-07 | 2004-10-07 | |
| US60/522,512 | 2004-10-07 | ||
| PCT/US2005/036304 WO2006042177A2 (en) | 2004-10-07 | 2005-10-07 | Mature dendritic cell compositions and methods for culturing same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013003939A Division JP2013121352A (ja) | 2004-10-07 | 2013-01-11 | 成熟樹状細胞組成物およびその培養方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008515439A JP2008515439A (ja) | 2008-05-15 |
| JP2008515439A5 true JP2008515439A5 (https=) | 2012-03-29 |
| JP5269412B2 JP5269412B2 (ja) | 2013-08-21 |
Family
ID=36148973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007535869A Expired - Fee Related JP5269412B2 (ja) | 2004-10-07 | 2005-10-07 | 成熟樹状細胞組成物およびその培養方法 |
| JP2013003939A Pending JP2013121352A (ja) | 2004-10-07 | 2013-01-11 | 成熟樹状細胞組成物およびその培養方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013003939A Pending JP2013121352A (ja) | 2004-10-07 | 2013-01-11 | 成熟樹状細胞組成物およびその培養方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20080145931A1 (https=) |
| EP (2) | EP2251418B1 (https=) |
| JP (2) | JP5269412B2 (https=) |
| KR (1) | KR101243577B1 (https=) |
| CN (1) | CN101080487B (https=) |
| AT (1) | ATE489455T1 (https=) |
| AU (1) | AU2005294150B2 (https=) |
| CA (1) | CA2577125C (https=) |
| DE (1) | DE602005025005D1 (https=) |
| DK (1) | DK1809737T3 (https=) |
| ES (1) | ES2861199T3 (https=) |
| TW (1) | TWI382843B (https=) |
| WO (1) | WO2006042177A2 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006042177A2 (en) | 2004-10-07 | 2006-04-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| JP5020935B2 (ja) | 2005-04-08 | 2012-09-05 | アルゴス セラピューティクス，インコーポレイティド | 樹状細胞組成物および方法 |
| US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| PL2066339T3 (pl) | 2006-09-18 | 2015-02-27 | Univ Arkansas | Kompozycje i sposoby zwiększania odpowiedzi immunologicznych |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| WO2008097926A2 (en) * | 2007-02-02 | 2008-08-14 | Yale University | Transient transfection with rna |
| DE102007006736B4 (de) | 2007-02-07 | 2012-01-12 | Dagmar Briechle | In-vitro Testkit zur tierversuchsfreien Bestimmung des sensibilisierenden Potentials einer Substanz |
| JP5331100B2 (ja) * | 2007-04-25 | 2013-10-30 | イミュアールエックス・インコーポレーテッド | Ｎｋｔアクチベータ、ｃｄ４０アゴニスト、及び任意選択的に抗原を含んでなるアジュバント組合せと、細胞性免疫において相乗的な増強を誘導するためのその使用 |
| EP2201100B1 (en) * | 2007-09-14 | 2016-03-16 | Vrije Universiteit Brussel | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| US9408909B2 (en) | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
| US8476419B2 (en) | 2007-09-14 | 2013-07-02 | Vrije Universiteit Brussel | Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| WO2009059018A1 (en) * | 2007-10-30 | 2009-05-07 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
| PT3097926T (pt) | 2007-11-01 | 2020-01-08 | Univ Guelph | Composições e métodos de potenciação das respostas imunitárias frente a eimeria |
| EP2072617A1 (en) * | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
| US20090263828A1 (en) * | 2008-04-16 | 2009-10-22 | Franco Lori | Novel assay for precursor T-cells having high proliferative capacity (PHPC-asay) |
| WO2010055900A1 (ja) | 2008-11-14 | 2010-05-20 | ディナベック株式会社 | 樹状細胞の製造方法 |
| AU2009323996A1 (en) | 2008-12-03 | 2011-07-07 | Institut Pasteur | Use of phenol-soluble modulins for vaccine development |
| CN102753700A (zh) * | 2009-09-04 | 2012-10-24 | 先正达参股股份有限公司 | 增加植物中多肽表达的翻译增强子元件堆叠 |
| CA3080368A1 (en) * | 2009-12-04 | 2011-06-09 | Stem Cell & Regenerative Medicine International, Inc. | Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts |
| ES2643646T3 (es) | 2010-01-21 | 2017-11-23 | The Board Of Trustees Of The University Of Arkansas | Vectores de vacuna y métodos para potenciar las respuestas inmunitarias |
| MX350306B (es) | 2010-06-09 | 2017-09-04 | Univ Arkansas | Vacuna y metodos para reducir una infeccion por campylobacter. |
| KR101749195B1 (ko) * | 2011-12-12 | 2017-06-20 | 셀 메디카 리미티드 | T 세포들을 증식시키는 방법 |
| AR094791A1 (es) | 2013-02-14 | 2015-08-26 | Univ Arkansas | Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria |
| AU2014239557B2 (en) | 2013-03-15 | 2019-01-03 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
| KR102257305B1 (ko) * | 2013-03-28 | 2021-05-28 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 미세유동 장치 및 분비물의 다세포 검정법에서의 그의 사용 방법 |
| JP2016081562A (ja) | 2014-10-09 | 2016-05-16 | ソニー株式会社 | 表示装置、表示装置の製造方法および電子機器 |
| US11254914B2 (en) | 2015-03-12 | 2022-02-22 | Health Research, Inc. | Enrichment of CD16+ monocytes to improve dendritic cell vaccine quality |
| CN105670994A (zh) * | 2016-02-28 | 2016-06-15 | 深圳爱生再生医学科技有限公司 | Dc诱导剂及其应用 |
| CN108884459B (zh) * | 2016-04-26 | 2024-04-02 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| KR102767638B1 (ko) | 2016-05-03 | 2025-02-20 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법 |
| JP2021502419A (ja) | 2017-11-07 | 2021-01-28 | コイミューン インコーポレイテッド | 樹状細胞治療のための方法および使用 |
| AU2019291069B2 (en) * | 2018-06-19 | 2026-02-19 | Fondazione Centro San Raffaele | Production of engineered dendritic cells and uses thereof |
| CA3106403A1 (en) * | 2018-07-15 | 2020-01-23 | Enochian BioPharma, Inc. | Methods and compositions using recombinant dendritic cells for cancer therapy |
| CN109797209B (zh) * | 2019-01-04 | 2021-07-16 | 中国人民解放军第二军医大学 | 一种树突状细胞和/或趋化性树突状细胞和/或其趋化状态和功能的特异性生物标志物 |
| MX2021012471A (es) * | 2019-04-11 | 2022-01-04 | Univ Arkansas | Aptameros de adn especificos de cd40 como adyuvantes de vacunas. |
| US20210030795A1 (en) * | 2019-06-17 | 2021-02-04 | Enochian BioPharma, Inc. | Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity |
| WO2025076303A1 (en) * | 2023-10-05 | 2025-04-10 | Amgen Inc. | Major histocompatibility complex (mhc)-associated peptide proteomics (mapps) assay for immunogenicity risk assessment of biotherapeutic attributes |
| WO2025147510A1 (en) * | 2024-01-05 | 2025-07-10 | Renovaro Biopharma Inc. | Methods and compositions using recombinant dendritic cells for cancer therapy |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3424893A1 (de) | 1984-07-06 | 1986-02-06 | Agfa-Gevaert Ag, 5090 Leverkusen | Photographisches silberhalogenidaufzeichnungsmaterial |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JP3068910B2 (ja) | 1990-11-08 | 2000-07-24 | 麒麟麦酒株式会社 | 新規スフィンゴ糖脂質、その製造法および使用 |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| US5981724A (en) * | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| ES2198025T3 (es) | 1991-10-25 | 2004-01-16 | Immunex Corporation | Anticuerpos contra cd40-l. |
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| EP0563485A1 (en) | 1992-03-30 | 1993-10-06 | Schering-Plough | In vitro generation of human dendritic cells and uses thereof |
| DE69333433T2 (de) | 1992-04-01 | 2004-12-02 | The Rockefeller University | Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung |
| TW261533B (https=) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| AU683026B2 (en) | 1992-10-22 | 1997-10-30 | Kirin Pharma Kabushiki Kaisha | Novel shingoglycolipid and use thereof |
| EP0694558B1 (en) | 1993-04-15 | 1999-01-27 | Kirin Beer Kabushiki Kaisha | Novel sphingoglycolipid and use thereof |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| DE4412794A1 (de) | 1994-04-14 | 1995-12-14 | Univ Ludwigs Albert | Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens |
| US6734014B1 (en) | 1996-02-08 | 2004-05-11 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for transforming dendritic cells and activating T cells |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| PL181496B1 (pl) | 1996-03-20 | 2001-07-31 | Politechnika Slaska Im Wincent | Sposób wytwarzania ß-naftolu PL |
| US6017527A (en) * | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
| EP0961824A4 (en) * | 1996-07-10 | 2003-01-29 | Immunex Corp | METHOD FOR ACTIVATING DENTRITIC CELLS |
| US7273753B2 (en) | 1996-08-02 | 2007-09-25 | Center Of Blood Research | Purification and uses of dendritic cells and monocytes |
| TW555562B (en) | 1996-12-27 | 2003-10-01 | Kirin Brewery | Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof |
| JP3495740B2 (ja) * | 1997-04-10 | 2004-02-09 | 麒麟麦酒株式会社 | α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤 |
| TW575420B (en) | 1997-09-22 | 2004-02-11 | Kirin Brewery | Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides |
| DE69840739D1 (de) | 1997-10-27 | 2009-05-28 | Merix Bioscience Inc | Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen |
| DE69940731D1 (de) | 1998-05-26 | 2009-05-28 | Genitrix Llc | Zusammensetzungen und verfahren zur modulation einer immunantwort auf ein antigen durch verabreichung von zytokine-beladenen zellen |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| AU5178800A (en) | 1999-06-01 | 2000-12-18 | Cornell Research Foundation Inc. | Activation of dendritic cells to enhance immunity |
| AU6934600A (en) * | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
| US20030077263A1 (en) | 1999-10-29 | 2003-04-24 | Immunex Corporation | Method of activating dendritic cells |
| US20030235908A1 (en) | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| US7063845B2 (en) * | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| JP4410913B2 (ja) | 2000-06-12 | 2010-02-10 | 壽製薬株式会社 | 新規糖脂質誘導体の製造方法 |
| JP5184732B2 (ja) * | 2000-06-19 | 2013-04-17 | ベス イスラエル デアコネス メディカル センター | Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法 |
| WO2001098317A2 (en) * | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| DE10041515A1 (de) | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
| AU2002232447A1 (en) | 2000-11-02 | 2002-05-15 | Immunex Corporation | Method of enhancing lymphocyte-mediated immune responses |
| US7405076B2 (en) * | 2000-11-14 | 2008-07-29 | Universite Libre De Bruxelles | Generation and use of dendritic cells |
| FR2819263B1 (fr) | 2001-01-10 | 2003-04-11 | Lco Sante | Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740 |
| DE60117167T2 (de) * | 2001-01-15 | 2006-10-05 | I.D.M. Immuno-Designed Molecules | Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen |
| US7767202B2 (en) | 2001-03-16 | 2010-08-03 | The Johns Hopkins University | Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules |
| EP1270732A1 (en) | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| EP1409648A1 (en) | 2001-07-25 | 2004-04-21 | I.D.M. Immuno-Designed Molecules | New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions |
| EP1434859A2 (en) | 2001-07-25 | 2004-07-07 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| US20040072347A1 (en) | 2001-07-27 | 2004-04-15 | Gerold Schuler | Generation of fully mature and stable dendritic cells from leukaphereses products for clinical applications |
| EP1437358B1 (en) | 2001-08-16 | 2006-10-18 | Daiichi Asubio Pharma Co., Ltd. | Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient |
| EP1444330A1 (en) * | 2001-11-07 | 2004-08-11 | Kirin Beer Kabushiki Kaisha | Expansion of t cells in vitro and expanded t cell populations |
| AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| AU2003295331A1 (en) | 2002-09-19 | 2004-04-23 | Centocor, Inc. | Method of inducing maturation of dendritic cells and uses therefor |
| BR0314640A (pt) | 2002-09-20 | 2005-08-02 | Kirin Brewery | Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| EP1567014B1 (en) | 2002-12-04 | 2011-09-28 | Baylor Research Institute | Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors |
| AU2003296439B2 (en) * | 2002-12-10 | 2009-05-07 | Argos Therapeutics, Inc. | In situ maturation of dendritic cells |
| SE0301109D0 (sv) | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
| US20050003533A1 (en) * | 2003-05-08 | 2005-01-06 | Pawel Kalinski | Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use |
| US7060111B2 (en) | 2003-07-03 | 2006-06-13 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Method for providing more vibrant, natural and long-lasting color to hair |
| CA2560969A1 (en) * | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
| WO2006042177A2 (en) * | 2004-10-07 | 2006-04-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
-
2005
- 2005-10-07 WO PCT/US2005/036304 patent/WO2006042177A2/en not_active Ceased
- 2005-10-07 ES ES10174970T patent/ES2861199T3/es not_active Expired - Lifetime
- 2005-10-07 KR KR1020077008070A patent/KR101243577B1/ko not_active Expired - Fee Related
- 2005-10-07 TW TW094135203A patent/TWI382843B/zh not_active IP Right Cessation
- 2005-10-07 AU AU2005294150A patent/AU2005294150B2/en not_active Ceased
- 2005-10-07 AT AT05804341T patent/ATE489455T1/de active
- 2005-10-07 DK DK05804341.5T patent/DK1809737T3/da active
- 2005-10-07 CA CA2577125A patent/CA2577125C/en not_active Expired - Lifetime
- 2005-10-07 US US11/664,899 patent/US20080145931A1/en not_active Abandoned
- 2005-10-07 US US11/246,387 patent/US8822223B2/en not_active Expired - Lifetime
- 2005-10-07 DE DE602005025005T patent/DE602005025005D1/de not_active Expired - Lifetime
- 2005-10-07 EP EP10174970.3A patent/EP2251418B1/en not_active Expired - Lifetime
- 2005-10-07 CN CN2005800337404A patent/CN101080487B/zh not_active Expired - Fee Related
- 2005-10-07 EP EP05804341A patent/EP1809737B9/en not_active Expired - Lifetime
- 2005-10-07 JP JP2007535869A patent/JP5269412B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-11 JP JP2013003939A patent/JP2013121352A/ja active Pending
-
2014
- 2014-08-29 US US14/473,868 patent/US9556455B2/en not_active Expired - Fee Related
-
2016
- 2016-12-20 US US15/385,559 patent/US11248209B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515439A5 (https=) | ||
| Boullart et al. | Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration | |
| Banchereau et al. | Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries? | |
| Manjunath et al. | Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes | |
| JP6114768B2 (ja) | 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法 | |
| Santini et al. | The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity | |
| JP4762887B2 (ja) | 付加的なサイトカインの非存在下でｇｍ−ｃｓｆを用いる単球樹状前駆細胞からの樹状細胞の産生 | |
| JP5425618B2 (ja) | 成熟樹状細胞組成物およびそれを培養するための方法 | |
| Nanjappa et al. | Effects of IL-7 on memory CD8+ T cell homeostasis are influenced by the timing of therapy in mice | |
| JP2005505270A5 (https=) | ||
| JP2009533025A5 (https=) | ||
| US20030124091A1 (en) | Endothelial cell derived hematopoietic growth factor | |
| JP5855018B2 (ja) | 腫瘍細胞増殖を阻害するための改善された組成物 | |
| KR20200023375A (ko) | 뎅기 바이러스 및 수지상 세포를 이용하는 암 요법을 위한 조성물 및 방법 | |
| Knippertz et al. | Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-γ | |
| Hoogendoorn et al. | Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy | |
| US20240122975A1 (en) | In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response | |
| Van den Bergh et al. | Characterization of interleukin‐15‐transpresenting dendritic cells for clinical use | |
| Watarai et al. | Induced pluripotency as a potential path towards i NKT cell-mediated cancer immunotherapy | |
| JP2006517108A (ja) | 培養されたｃｄ１４＋抗原提示細胞 | |
| KR101270999B1 (ko) | 결핵균의 Ｒｖ２２９９ｃ 단백질을 이용한 수지상 세포의 성숙방법 | |
| EP1959007A1 (en) | Method for providing mature dendritic cells | |
| Yi et al. | 3-day monocyte-derived dendritic cells stimulated with a combination of OK432, TLR7/8 ligand, and prostaglandin E2 are a promising alternative for cancer immunotherapy | |
| Ye et al. | Human dendritic cells engineered to express alpha tumor necrosis factor maintain cellular maturation and T-cell stimulation capacity | |
| JP7790088B2 (ja) | セクレトーム検出方法及びｔ細胞標識用培地 |